CFTR and cystic fibrosis: A double-anonymized, placebo-controlled trial (n = 8 cystic fibrosis patients given DNA-lipid complexes alone, n = 8 control patients given lipids/placebo alone) found that pulmonary administration of CFTR DNA-lipid complexes (but not placebo/lipids alone) significantly corrected chloride abnormalities identified by measurement of in vivo potential difference and chloride efflux [108].